Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1891
Title: Antiangiogehic Drugs for Colorectal Cancer: Exploring New Possibilities
Authors: FERRAROTTO, RenataHOFF, Paulo M.
Citation: CLINICAL COLORECTAL CANCER, v.12, n.1, p.1-7, 2013
Abstract: Angiogenesis is essential to cancer development and progression, and its inhibition has been shown to benefit patients with several different malignancies. A considerable number of antiangiogenic compounds have been evaluated for the treatment of colorectal cancer; but only bevacizumab and aflibercept were able to demonstrate a survival benefit in phase III trials. In this review, we discuss important aspects of the interrelationship between tumor cells and the microenvironment leading to tumor progression, with a focus on angiogenesis. Clinical data on antiangiogenic therapies for colorectal cancer in the metastatic and adjuvant settings, as well as the potential use of antiangiogenics beyond tumor progression are analyzed. The need to identify surrogate biomarkers towards a more personalized approach in oncology is emphasized as this is becoming increasingly important in drug development. Clinical Colorectal Cancer, Vol. 12, No. 1, 1-7 (C) 2013 Elsevier Inc. All rights reserved.
Appears in Collections:Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24

Files in This Item:
File Description SizeFormat 
art_HOFF_Antiangiogehic_Drugs_for_Colorectal_Cancer_Exploring_New_Possibilities_2013.PDF
  Restricted Access
publishedVersion (English)322.43 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.